ArticleTuberculosis (Edinburgh, Scotland)2009
High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.
Article in Tuberculosis (Edinburgh, Scotland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed.
- Identification of chemical features for improved outer membrane permeation in mycobacteria using machine learning.Nature microbiology · 2026Article
- A Trehalose-Based Phenotypic Screen Identifies Candidate Inhibitors ofAntibiotics (Basel, Switzerland) · 2026Article
- Quantifying uncertainty of tuberculosis drug susceptibility range from single-microplate test.MethodsX · 2026Article
- Questiomycin A demonstrates antibacterial activity against Mycobacterium tuberculosis by directly targeting FabD.Communications biology · 2026Article
- A Series of Pyrazolo-Quinazoline Amines Inhibits the CytochromeJournal of medicinal chemistry · 2026Article
- Targeting opportunities presented by the pyrimidine biosynthesis pathway in Mycobacterium tuberculosis: a brief review.Biochemical Society transactions · 2026Review
- Development of machine learning models to identify potentially active compounds against tuberculosis.Scientific reports · 2025Article
- Genetic and Cheminformatic Characterization ofACS infectious diseases · 2025Article
- Article
- Identification of chemical features that influence mycomembrane permeation and antitubercular activity.bioRxiv : the preprint server for biology · 2025Article
- Exploration of vanoxerine analogues as antibacterial agents.The Journal of antibiotics · 2025Article
- Identification of natural potent inhibitors against Mycobacterium tuberculosis isocitrate lyase: an in silico study.Molecular diversity · 2024Article
- Synthesis, docking and characterization of some novel 5-(S-alkyl)-1.3.4-thiadiazole-2-carboxamide derivatives as anti-inflammatory and antibacterial agents.BMC chemistry · 2024Article
- A high-throughput response to the SARS-CoV-2 pandemic.SLAS discovery : advancing life sciences R & D · 2024Article
- High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.Metabolites · 2023Review
- Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis.Microbiology spectrum · 2023Article
- Recent Advances of DprE1 Inhibitors againstACS omega · 2022Review
- Glycosylated Flavonoid Compounds as Potent CYP121 Inhibitors ofBiomolecules · 2022Article
- Identification of Small Molecule Inhibitors against Mycobacteria in Activated Macrophages.Molecules (Basel, Switzerland) · 2022Article
- OvercomingActa pharmaceutica Sinica. B · 2022Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
There is an urgent need for the discovery and development of new antitubercular agents that target new biochemical pathways and treat drug resistant forms of the disease. One approach to addressing this need is through high-throughput screening of medicinally relevant libraries against the whole bacterium in order to discover a variety of new, active scaffolds that will stimulate new biological research and drug discovery. Through the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (www.taacf.org), a large, medicinally relevant chemical library was screened against M. tuberculosis strain H37Rv. The screening methods and a medicinal chemistry analysis of the results are reported herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.